Actym Closes $59.5 Million Series A with New $25.5 Million Extension
Actym Therapeutics adds $25.5 million to close its Series A with $59.5 million total New investor GKCC LLC joins syndicate Capital will propel lead program ACTM-838 into first-in-human oncology trial and further advance proprietary STACT platform BERKELEY, CA — October 18, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today […]
Article Date
October 18, 2023
This article is featured on another website.
Go to article
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
July 24, 2026
HiRO and Monash Health Sign Site Alliance Agreement at BIO Asia-Taiwan
HiRO Partners with Monash Health to Speed Up Complex Clinical Trials HiRO has formalized a…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…
July 15, 2026
Glioblastoma Clinical Trials – Where Progress is Actually Happening in Glioma Research
Where Glioma Research Is Actually Moving Forward Glioblastoma (GBM) is the most common and most…